RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:410 shares Excellent point. And the stock surely will jump well beyond the exercise price on good cancer news that would trigger a phase II trial. I have forgotten when the warrants expire - probably well after the need for the money for a phase II. Warrant holders could choose to wait until the last minute to convert to common and the timing may be off for TH's needs. Something to look into.
jfm1330 wrote: At the moment the financing led to only a 18% increase from around 80 millions share to 95 millions. Warrants will need to be execized for the 1/3 dilution to happen. Exercise price is US$3.18. So we need to remember that yes this added dilution would be bad if warrants are exercizedsince January 2024, but it would give the company an extra 45 M$. So success in oncology would come with 45 M$, more than enough to pay for three phase II studies.
quote=SPCEO1]Sorry, you are incorrect again. Sales are higher - not by a ton but still up. The stock is down by a third mostly because the ONO led to about a 1/3 increase in the number of shares.
Momo25 wrote: You are dead wrong SPECEO. Verbiage idoen't change tha facts. Question for you: If the drug sales were really boosted when Paul came in, then explain to me why the share lost a 1/3rd of its value since then?
[/quote]